All In Biotech

Drug Trial Radar · NCT01342081

DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%

A Double-masked Study of DE-111 Ophthalmic Solution Versus Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5% in Patients With Primary Open Angle Glaucoma or Ocular Hypertension -Phase 3, Confirmatory Study-

Last checked: Nov 20, 2026Latest source record: Jun 15, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

489

Actual

Start

May 2011

Primary completion

Sep 2012

Sponsor

Sponsor type
Industry
First posted
Apr 26, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 20 years

Summary

As written by the sponsor on the registry.

DE-111 ophthalmic solution will be evaluated for superiority in comparison with Tafluprost 0.0015% ophthalmic solution, or for non-inferiority in comparison with Tafluprost 0.0015% and Timolol ophthalmic solution 0.5% used concomitantly, in IOP(intraocular pressure) -lowering effect in primary open-angle glaucoma or ocular hypertension patients, in a multicenter, randomized, double-masked, parallel-group comparison study. Safety will be compared and evaluated as well.

Conditions

  • Open Angle Glaucoma
  • Ocular Hypertension

Interventions

  • DE-111 ophthalmic solutionDrug

  • Tafluprost ophthalmic solution 0.0015%Drug

  • Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Mean Diurnal IOP(Intraocular Pressure) at End of StudyTime frame: Week 0(Baseline) and Week 4(End of Study)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Santen study sites

    Osaka, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.